News & Updates

No apparent harm seen with early pregnancy ozanimod exposure, but caution still urged

23 Dec 2023 by

Exposure to ozanimod during early pregnancy does not appear to pose risks of adverse pregnancy outcomes and foetal health despite recommendations to avoid getting pregnant while receiving ozanimod and for 3 months after treatment discontinuation, according to a study.

No apparent harm seen with early pregnancy ozanimod exposure, but caution still urged

23 Dec 2023

Does appendix removal raise risk of Crohn’s disease?

22 Dec 2023 by

Individuals who have undergone an appendectomy may be at heightened risk of Crohn’s disease, according to the results of a systematic review and meta-analysis.

Does appendix removal raise risk of Crohn’s disease?

22 Dec 2023

Faecal microbiota spores deliver benefit in older patients with C. diff recurrence

22 Dec 2023 by

In an integrated analysis of two phase III ECOSPOR trials presented at AIBD 2023, faecal microbiota spores (ie, live-brpk) demonstrated favourable safety and efficacy signals for the treatment of recurrent Clostridioides (C.) difficile infection (CDI) in older individuals.

Faecal microbiota spores deliver benefit in older patients with C. diff recurrence

22 Dec 2023

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

22 Dec 2023

People with nocturnal gastroesophageal reflux (GER) and habitual snoring are vulnerable to developing asthma and respiratory symptoms, according to a study.

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

22 Dec 2023

Risankizumab as induction therapy induces clinical remission in UC

22 Dec 2023 by

Induction therapy with risankizumab, a monoclonal antibody neutralizing interleukin-23p19, resulted in significantly higher clinical remission rates among patients with moderate-to-severe ulcerative colitis (UC) compared with placebo, according to the INSPIRE trial presented at AIBD 2023.

Risankizumab as induction therapy induces clinical remission in UC

22 Dec 2023

Tofacitinib in ulcerative colitis: UEGW 2023 updates

19 Dec 2023 by

At the United European Gastroenterology Week (UEGW) 2023 held in Copenhagen, Denmark, researchers presented latest findings on tofacitinib in ulcerative colitis (UC). Topics covered included identification of factors associated with tofacitinib treatment response and maintenance of response, histological outcomes following treatment, and long-term safety data from the global tofacitinib UC clinical programme.

Tofacitinib in ulcerative colitis: UEGW 2023 updates

19 Dec 2023

Original New Drug Application Approvals by US FDA (01-15 December 2023)

18 Dec 2023

New drug applications approved by US FDA as of 01-15 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 December 2023)

18 Dec 2023

Zonulin a promising biomarker for preclinical coeliac disease screening

18 Dec 2023

Zonulin levels appear to substantially increase in the months leading up to a diagnosis of coeliac disease, as reported in a study. Additionally, exposure to a greater number of antibiotic courses contribute to an increase in zonulin levels in individuals with coeliac disease, highlighting a potential role for the marker in preclinical screening.

Zonulin a promising biomarker for preclinical coeliac disease screening

18 Dec 2023

Original New Drug Application Approvals by US FDA (16-30 November 2023)

13 Dec 2023

New drug applications approved by US FDA as of 16-30 November 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2023)

13 Dec 2023

Novel therapies tied to drop in colectomy rate in paediatric UC

05 Dec 2023

The risk of colectomy in paediatric onset ulcerative colitis (UC) has significantly decreased at the population level along with an increase in the use of immunosuppressants and antitumour necrosis factor (anti-TNF), reports a study.

Novel therapies tied to drop in colectomy rate in paediatric UC

05 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

No apparent harm seen with early pregnancy ozanimod exposure, but caution still urged

No apparent harm seen with early pregnancy ozanimod exposure, but caution still urged

Does appendix removal raise risk of Crohn’s disease?

Does appendix removal raise risk of Crohn’s disease?

Faecal microbiota spores deliver benefit in older patients with C. diff recurrence

Faecal microbiota spores deliver benefit in older patients with C. diff recurrence

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

Risankizumab as induction therapy induces clinical remission in UC

Risankizumab as induction therapy induces clinical remission in UC

Tofacitinib in ulcerative colitis: UEGW 2023 updates

Tofacitinib in ulcerative colitis: UEGW 2023 updates

Original New Drug Application Approvals by US FDA (01-15 December 2023)

Original New Drug Application Approvals by US FDA (01-15 December 2023)

Zonulin a promising biomarker for preclinical coeliac disease screening

Zonulin a promising biomarker for preclinical coeliac disease screening

Original New Drug Application Approvals by US FDA (16-30 November 2023)

Original New Drug Application Approvals by US FDA (16-30 November 2023)

Novel therapies tied to drop in colectomy rate in paediatric UC

Novel therapies tied to drop in colectomy rate in paediatric UC